Showing results (161-170 of 445) with videos related to

Sort By:
Pageof 45
BMC Medical Education|November 23, 2023
"Tell me what is 'better'!" How medical students experience feedback, through the lens of self-regulatory learningMuirne Spooner, James Larkin, Siaw Cheok Liew, et al.
Current Problems in Cancer|February 24, 2021
Pituitary enlargement following ipilimumab without long term endocrine dysfunctionEdson Nogueira, Arjun Menon, Anastasia Dede, et al.
BJGP Open|August 8, 2025
Pharmaceutical company promotional payments to English general practices: longitudinal studyShai Mulinari, Minahil Malik, James Larkin, et al.
Anticancer Research|July 4, 2012
Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinomaJames Larkin, Norbert Esser, Emiliano Calvo, et al.
JCO Clinical Cancer Informatics|June 16, 2026
Development of a Digital Phenotype for Immune-Related ColitisJasmine C Teng, Leon J Worth, Karin A Thursky, et al.
Cell|January 28, 2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionKevin Litchfield, James L Reading, Clare Puttick, et al.
Translational Oncology|July 4, 2017
Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma PatientsSimon Matoori, Yeeliang Thian, Dow-Mu Koh, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2015
Prognostic score for patients with advanced melanoma treated with ipilimumabStefan Diem, Benjamin Kasenda, Juan Martin-Liberal, et al.
BMC Primary Care|February 27, 2025
How do people with multimorbidity prioritise healthcare when faced with tighter financial constraints? A national survey with a choice experiment componentJames Larkin, Louise Foley, Shane Timmons, et al.
Radiology|May 30, 2014
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinibYeeliang Thian, Andreas Gutzeit, Dow-Mu Koh, et al.
Pageof 45